Skip to main content
. 2024 Feb 27;10(1):e004062. doi: 10.1136/rmdopen-2023-004062

Figure 3.

Figure 3

Patient-reported outcomes for delay groups over 3 years of follow-up. (A) Functional ability measured with the HAQ, (B) disease impact measured with the PsAID-12, (C) mean general health and (D) mean pain in psoriatic arthritis patients stratified for the delay groups short (<12 weeks), intermediate (12 weeks to 1 year) and long (>1 year). (A, B) The predicted response after correcting for age and sex, while figure (C, D) the mean with 95% CI. *A significant difference between the short delay group and the long delay group. ***A significant difference between the short delay group and the intermediate delay group. HAQ, Health Assessment Questionnaire; PsAID-12, Psoriatic Arthritis Impact of Disease; VAS, Visual Analogue Scale.